Pharma Markets

US Wet Age-Related Macular Degeneration Market Analysis and Competitive Landscape Highlights

By Fore Pharma | Published Date: May 24, 2020 | On-Demand Data

US Wet Age-Related Macular Degeneration Market Analysis and Competitive Landscape Highlights – 2020, provides comprehensive insights into Wet Age-Related Macular Degeneration pipeline products, Wet Age-Related Macular Degeneration epidemiology, Wet Age-Related Macular Degeneration market valuations and forecast, Wet Age-Related Macular Degeneration drugs sales and competitive landscape in the US.

Research Scope:

– Wet Age-Related Macular Degeneration Pipeline: Drugs in clinical trials for the treatment of Wet Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
– Wet Age-Related Macular Degeneration Epidemiology: Number of patients diagnosed (prevalence) with Wet Age-Related Macular Degeneration in the US
– Drugs sales: Sales revenues for Wet Age-Related Macular Degeneration drugs in the US
– Market valuations: US Wet Age-Related Macular Degeneration market size for in 2019; find out how the market advanced from 2016 and forecast to 2025
– Drugs market share: Market shares for key Wet Age-Related Macular Degeneration drugs in the US

This research helps executives to

– Support monitoring and reporting national Wet Age-Related Macular Degeneration market analysis and sales trends
– Track competitor drugs sales and market share in the US Wet Age-Related Macular Degeneration market
– Track competitive developments in Wet Age-Related Macular Degeneration market and present key issues and learnings
– Synthesize insights for Wet Age-Related Macular Degeneration market and products to drive business performance
– Answer key business questions about the Wet Age-Related Macular Degeneration market
– Evaluate commercial market opportunity assessment, positioning, and segmentation for Wet Age-Related Macular Degeneration products
– Supports decision making in R&D to long term marketing strategies

Table of Contents


1) Wet Age-Related Macular Degeneration Treatments
2) Wet Age-Related Macular Degeneration Drugs Pipeline
3) US Wet Age-Related Macular Degeneration Epidemiology
4) Marketed Drugs for Wet Age-Related Macular Degeneration in the US
5) Wet Age-Related Macular Degeneration Market Size and Forecast
6) Wet Age-Related Macular Degeneration Drugs Sales and Forecast
7) Wet Age-Related Macular Degeneration Market Competitive Landscape
8) Methodology
9) Contact us

List of Tables


1. Wet Age-Related Macular Degeneration Phase 3 Clinical Trials, 2020
2. Wet Age-Related Macular Degeneration Phase 2 Clinical Trials, 2020
3. Wet Age-Related Macular Degeneration Phase 1 Clinical Trials, 2020
4. Wet Age-Related Macular Degeneration Epidemiology, US, 2016 – 2025
5. Marketed Drugs for Wet Age-Related Macular Degeneration, US, 2019
6. Wet Age-Related Macular Degeneration Market Size and Forecast ($mn), US, 2016 – 2025
7. Wet Age-Related Macular Degeneration Drugs Sales ($mn), US, 2016 – 2025

List of Figures


1. Wet Age-Related Macular Degeneration Epidemiology, US, 2016 – 2025
2. Wet Age-Related Macular Degeneration Market Size and Forecast ($mn), US, 2016 – 2025
3. Wet Age-Related Macular Degeneration Drugs Market Share (%), US, 2019

Format


Dispatch format is XLSX.

Purchase Checkout Added to cart
face
  • Contact Nick
  •  Email
  •  Contact
  • I was looking for specific epidemiology and utilization data for our emerging therapy situation analysis. It was time sensitive. Your team helped me with the right data and methodologies. Thank you very much.
    - Director, Big Pharma

    About

    • About us
    • Research Store
    • Research Store
    • News
    • Contact

    Trusted By
    Top Companies